Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

nContact Surgical

Request full access

Medical device company that develops devices supporting endoscopic treatments for heart rhythm disorders

Morrisville, United StatesFounded 2004Biotech & Life Sciences

About nContact Surgical

nContact Surgical, founded in 2005 by Sidney Fleischman and Jim Whayne, specialized in developing medical devices for less invasive cardiac ablation procedures to treat atrial fibrillation (AFib). Initially named nContact Surgical, the company rebranded to nContact Inc. in 2011 to reflect its focus on less invasive, endoscopic approaches. The firm operated out of Morrisville, North Carolina, and focused on the market of patients with heart rhythm disorders, particularly those with enlarged atria who lacked reliable treatment alternatives.

The company's business revolved around the design, manufacturing, and sale of its cardiac ablation technology to healthcare facilities. A key part of its strategy involved fostering collaboration between cardiac surgeons and electrophysiologists. nContact's technology facilitates a multidisciplinary therapy known as the Convergent procedure, where a surgeon performs a closed-chest epicardial ablation, which is then complemented by an electrophysiologist's endocardial catheter ablation. This approach aimed to provide a more comprehensive treatment for persistent AFib. Throughout its history, nContact raised significant capital, securing a total of $67.7 million over eight funding rounds from investors including Harbert Venture Partners, ZMV Associates, and Hercules Capital.

nContact's flagship product was the EPi-Sense Guided Coagulation System with VisiTrax. This system was designed for the coagulation of cardiac tissue using radiofrequency (RF) energy. Its unique features included the integration of suction to ensure stable contact with the beating heart, perfusion, and RF energy delivery. The EPi-Sense device also incorporated embedded sensors to provide real-time electrical feedback, allowing physicians to map the heart and verify the completeness of lesions during the procedure. This technology received CE Mark approval in Europe for treating atrial fibrillation and atrial flutter and was cleared by the FDA in the U.S. for endoscopic coagulation of cardiac tissue. A significant milestone was the initiation of the CONVERGE IDE clinical trial, a head-to-head study evaluating the Convergent Procedure against catheter ablation for persistent AFib. In October 2015, nContact was acquired by AtriCure, Inc. for approximately $99 million in a cash-and-stock deal, with potential for an additional $50 million in milestone payments. The acquisition was a strategic move for AtriCure to expand its presence and product offerings in the AFib market.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
13
Open positions
None listed
Dealroom signal
56.6/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Human Resources, Biotechnology, Surgery, Cardiology and cardiovascular, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Oct 2015 $149M $149M AtriCure —
DEBTDebt Nov 2014 $20M — Hercules Capital —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

nContact Surgical website traffic

Latest recorded traffic for nContact Surgical is 230 monthly website visits. nContact Surgical's team grew 0% over the past year.

Latest monthly visits230 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

nContact Surgical in the Morrisville ecosystem

Live from Dealroom

The nContact Surgical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Intersouth Partners
  • Finistere Ventures
  • Massey Burch Capital Corporation

Series B and later3 investors entered at this stage

  • Harbert Growth Partners
  • ZMV Associates
  • Hercules Capital

Other known investors1 additional known investor

  • AtriCure
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Morrisville HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about nContact Surgical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See nContact Surgical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.